Treatments of tinea pedis

Dermatologic Clinics

Volumn 21, Issue 3, 2003, Pages 431-462

  Gupta, Aditya K ^a,b,e   Chow, Melody ^b   Daniel, C Ralph ^c   Aly, Raza ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

10 UNDECENOIC ACID; AJOENE; ALLYLAMINE; BENZYLAMINE; BIFONAZOLE; BUTENAFINE; CICLOPIROX; CLOTRIMAZOLE; ECONAZOLE; FENTICONAZOLE; FLUCONAZOLE; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; LANOCONAZOLE; MICONAZOLE; NAFTIFINE; NETICONAZOLE; OXICONAZOLE; PLACEBO; SALICYLIC ACID DERIVATIVE; SULCONAZOLE; TERBINAFINE; TOLCICLATE; TOLNAFTATE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ALLERGIC REACTION; AMENORRHEA; ANTIFUNGAL ACTIVITY; BLISTER; CONJUNCTIVITIS; DERMATOPHYTE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; EDEMA; EPIDIDYMITIS; FUNGUS GROWTH; GROWTH INHIBITION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERHIDROSIS; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INDIGESTION; INFECTION PREVENTION; NAUSEA; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; SKIN INFECTION; STOMACH PAIN; TINEA PEDIS; VERTIGO; VOMITING;

EID: 0042515032     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00032-9     Document Type: Review

References (98)

1. Odom R. Pathophysiology of dermatophyte infections. J Am Acad Dermatol 1993;28(5 pt 1):S2-7.
2. Martin AG, Kobayashi GS. Superficial fungal infection: dermatophytosis, tinea nigra, peidra. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's Dermatology in General Medicine, vol 2. New York: McGraw-Hill; 1999. p. 2349-51.
3. Masri-Fridling GD. Dermatophytosis of the feet. Dermatol Clin 1996;14:33-40.
4. Elgart ML, Warren NG. The superficial and subcutaneous mycoses. In: Moschella SL, Hurley HJ, editors. 3rd edition. Dermatology, vol 1. Philadelphia: WB Saunders; 1992. p. 880-6.
5. Gupta AK, Elewski BE. Nondermatophytes causes of onychomycosis and superficial mycoses. Curr Top Med Mycol 1996;7:87-97.
6. Elgart ML, Warren NG. The superficial and subcutaneous mycoses. In: Moschella SL, Hurley HJ, editors. 3rd edition. Dermatology. vol 1. Philadelphia: WB Saunders; 1992. p. 886-7.
7. Daniel CR, Gupta AK, Daniel MP, Daniel CM. Two feet-one hand syndrome: a retrospective multicentre survey. Int J Dermatol 1997;36:658-60.
8. Brooks KE, Bender JF. Tinea pedis: diagnosis and treatment. Clin Podiatr Med Surg 1996;13:31-46.
9. Hay RJ, Moore M. Mycology: tinea pedis. In: Champion RH, Burton JL, Bums DA, et al, editors. 6th edition. Rook/Wilkinson/Ebling textbook of dermatology, vol 2. United Kingdom: Blackwell Science; 1998. p. 1308-10.
10. Odom RB, James WD, Berger TG. Diseases resulting from fungi and yeasts. In: Odom RB, James WD, Berger TG, editors. Andrews' diseases of the skin: clinical dermatology. 9th edition. Philadelphia: WB Saunders; 2000. p. 372-9.
11. Leyden JJ, Aly R. Tinea pedis. Semin Dermatol 1993; 12:280-4.
12. Zaias N, Battistini F, Gomez-Urcuyo F, Rojas RF, Ricart R. Treatment of "tinea pedis" with griseofulvin and topical antifungal cream. Cutis 1978;22:196-9.
13. th Edition. Bethesda, MD: American Society of Health-System Pharmacists; 2002. p. 81-129, 3361-404.
14. United States Pharmacopeial Convention, Inc. reviewers. USP DI. 22nd edition. Drug Information for the Health Care Professional, vol 1. Colorado: Micromedex Thompson Healthcare; 2002. p. 329-38.
15. Tanuma H, Nishiyama S. Clinical evaluation of bifonazole for moccasin-type tinea pedis. Mycoses 1997;40: 223-8.
16. Smith EB, Tschen E. Treatment of interdigital tinea pedis and tinea versicolor with bifonazole 1% solution applied once daily. In: Fromtling RA, editor. Recent trends in the discovery, development and evaluation of antifungal agents. Philadelphia: JR Prous Science Publishers; 1987. p. 407-14.
17. Barkes L, Hill D, Dill G, Reeves JE, Wuntch R, Scherer PR. Investigation of clotrimazole usage in finea pedis without nail involvement. J Am Podiatr Assoc 1979;69: 296-305.
18. Smith EB, Graham JL, Urlich JA. Topical clotrimazole in tinea pedis. South Med J 1977;70:47-8.
19. Greer D, Jolly HW. Comparative trial of a two-dosage schedule of ketoconazole 2% cream for the treatment of tinea pedis. J Am Acad Dermatol 1987;17: 53-6.
20. Greer DL. Topical treatment for moccasin-type tinea pedis. J Am Acad Dermatol 1987;16(3 pt 1):554-8.
21. Lester M. Ketoconazole 2 percent cream in the treatment of tinea pedis, tinea cruris, and tinea corporis. Cutis 1995;55:181-3.
22. Shellow WVR. 2% Miconazole nitrate powder in aerosol spray form: its efficacy in treating tinea pedis. J Int Med Res 1982;10:28-31.
23. Pierard GE, Wallace R, De Doncker P. Biometrological assessment of the preventive effect of a miconazole spray powder on athlete's foot. Clin Exp Dermatol 1996;21:344-6.
24. Elewski BE, Jones T, Zaias N. Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. Cutis 1996; 58:305-7.
25. Benfield P, Clissold SP. Sulconazole: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 1988;35:143-53.
26. Tanenbaum L, Anderson C, Rosenberg MJ, Howard W, McDaniel W, Neimanis A, et al. Sulconazole nitrate 1.0 percent cream: a comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. Cutis 1982;30:105-7, 115, 118.
27. Akers WA, Lane A, Lynfield Y, Greenberg J, Hall J, Mangan C, et al. Sulconazole nitrate 1% cream in the treatment of chronic moccasin-type tinea pedis caused by Trichophyton rubrum. J Am Acad Dermatol 1989; 21(4 pt 1):686-9.
28. Tanuma H, Doi M, Yaguchi Y, Ohta Y, Nishiyama S, Sekiguichi K, et al. Efficacy of oral fluconazole in tinea pedis of the hyperkeratotic type: stratum comeum levels. Mycoses 1998;41:153-62.
29. Decroix J. Tinea pedis (moccasin-type) treated with itraconazole. Int J Dermatol 1995;34:122-4.
30. Bonifaz A, Saul A. Treatment of tinea pedis with a single pulse of itraconazole. Eur J Dermatol 2002;12: 157-9.
31. Schuller J, Remme JJ, Rampen FJH, Van Neer FC. Itraconazole in the treatment of tinea pedis and tinea manuum: comparison of two treatment schedules. Mycoses 1998;41:515-20.
32. De Doncker P, Gupta AK, Marynissen G, Stoffels P, Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997;37:969-74.
33. Savin R, De Villez RL, Elewski B, Hong S, Jones T, Lowe N, et al. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. J Am Acad Dermatol 1997;36(2 pt 1):S15-9.
34. Monk JP, Brogden RN. Naftifine: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 1991;42:659-72.
35. Berman B, Ellis C, Leyden J, Lowe N, Savin R, Shupack J, et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis: results of placebo-controlled, double-blind, multicenter trials. J Am Acad Dermatol 1992;26: 956-60.
36. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil): a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989;14:124-7.
37. Faergemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum comeum, dermis-epidermis (without stratum comeum), hair, sebum and eccrine sweat. Acta Derm Venereol 1991;71:322-6.
38. Gupta AK. Ciclopirox: an overview. Int J Dermatol 2001;40:1-7.
39. Kligman AM, Bogaert H, Cordero C, Duncan WC, Roenigk HH, Savin RC, et al. Evaluation of ciclopirox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative study. Clin Ther 1985; 7:409-17.
40. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part 1. J Am Acad Dermatol 1994; 30(5 pt 1):677-98.
41. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30: 911-30.
42. Roberts DT, Cox NH, Gentles JC, Babu KK. Comparison of ketoconazole and griseofulvin in the treatment of tinea pedis. J Med Vet Mycol 1987;25:346-50.
43. Smith EB, Dickson JE, Knox JM. Tolnaftate powder in prophylaxis of tinea pedis. South Med J 1974;67: 776-8.
44. Tschen EH, Becker LE, Ulrich JA, Hoge WH, Smith EB. Comparison of over-the-counter agents for tinea pedis. Cutis 1979;23:696-8.
45. Fuerst JF, Cox GF, Weaver SM, Duncan WC. Comparison between undecylenic acid and tolnaftate in the treatment of tinea pedis. Cutis 1980;25:544-9.
46. Chretien JH, Esswein JG, Sharpe LM, Kiely JJ, Lyddon FE. Efficacy of undecylenic acid-zinc undecylenate powder in culture positive tinea pedis. Int J Dermatol 1980;19:51-4.
47. Nozickova M, Koudelkova V, Kulikova Z, Malina L, Urbanowski S, Silny W. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol 1998; 37:703-5.
48. Svejgaard E, Avnstorp C, Wanscher B, Nilsson J, Heremans A. Efficacy and safety of short-term itraconazole in tinea pedis: a double-blind, randomized, placebo-controlled trial. Dermatology 1998;197: 368-72.
49. Smith S, Houpt K, Rich P, LaMarca A, Weinberg JM, Alferez TS, et al. Short-duration oral terbinafine for the treatment of tinea pedis for the treatment of tinea pedis in HIV-positive patients. Cutis 2001;68(1 suppl): 30-9.
50. Selcuki D, Memisoglu H, Katogyan A, et al. A multicenter clinical trial of systemic terbinafine treatment in tinea pedis, tinea corporis and tinea cruris [abstract 50]. Presented at the Dermatology 2000 Vienna Conference. Vienna, Austria, 1993, p 106.
51. White JE, Perkins PJ, Evans EGV. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum. Br J Dermatol 1991;125: 260-2.
52. Savin R, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. J Am Acad Dermatol 1990;23(4 pt 2): 804-7.
53. Tanuma H, Doi M, Sato N, Nishiyama S, Abe M, Kume H, et al. Bifonazole (Mycospor cream) in the treatment of moccasin-type tinea pedis: comparison between combination therapy of bifonazole cream + 10% urea ointment (Urepearl) and occlusive dressing therapy with the same agents. Mycoses 2000;43: 129-37.
54. Galimberti RL, Belli L, Negroni R, Castro JM, Rohwedder R, Tuculet MA. Treatment of tinea pedis inter-digitalis with bifonazole, 1% gel. Dermatologica 1984; 169(suppl 1):107-9.
55. Spiekermann PH, Young MD. Clinical evaluation of clotrimazole. Arch Dermatol 1976;112:350-2.
56. Albanese G, Di Cintio R, Giorgetti P, Galbiati G, Ciampini M. Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder. Mycoses 1992;35:157-9.
57. Tanuma H, Tanuma M, Abe M, Kume H. Usefulness of lanoconazole (Astat) cream in the treatment of hyperkeratotic type tinea pedis: comparative study of monotherapy and combination therapy with 10% urea ointment (Pastaron). Mycoses 2001;44:181-90.
58. Gentles JC, Jones GR, Roberts DT. Efficacy of miconazole in the topical treatment of tinea pedis in sportsmen. Br J Dermatol 1975;93:79.
59. Brugmans JP, van Cutsem JM, Thienpoint DC. Treatment of long-term tinea pedis with miconazole. Arch Dermatol 1970;102:428-32.
60. Tsuboi R, Matsumoto T, Ogawa H. Hyperkeratotic chronic tinea pedis treated with neticonazole cream. Int J Dermatol 1996;35:371-3.
61. Reyes BL, Beutner KR, Sullen SI, Rosen T, Shupack JL, Weinstein MB. Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. Int J Dermatol 1998;37: 450-3.
62. Tschen E, Elewski B, Gorsulowsky DC, Pariser DM. Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997;36(2 pt 1):S9-14.
63. Naftifine Gel Study Group. Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Cutis 1991;48:85-8.
64. Korting HC, Tietz H-J, Brautigam M, Mayser P, Rapatz G, Paul C. One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. Med Mycol 2001;39:335-40.
65. Lebwohl M, Elewski B, Eisen D, Savin RC. Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris. Cutis 2001;67:261-6.
66. Tanuma H, Doi M, Ohta Y, Nishiyama S, Katsuika K, Kaneko S, et al. Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. Mycoses 2000; 43:417.
67. Evans EGV, Seaman RAJ, James IGV. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatol 1994;130:83-7.
68. Savin R, Atton AV, Bergstresser PR, Elewski B, Jones HE, Levine N, et al. Efficacy of terbinafine 1% cream in the treatment of moccasin-type tinea pedis: results of placebo-controlled multicenter trials. J Am Acad Dermatol 1994;30:663-7.
69. Savin RC. Treatment of chronic tinea pedis (athlete's foot type) with topical terbinafine. J Am Acad Dermatol 1990;23(4 pt 2):786-9.
70. Smith EB, Noppakun N, Newton RC. A clinical trial of topical terbinafine (a new allylamine antifungal) in the treatment of tinea pedis. J Am Acad Dermatol 1990; 23(4 pt 2):790-4.
71. Aly R, Maibach HI, Bagatell FK, Dittmar W, Hanel H, Falanga V, et al. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis. Clin Ther 1989;11: 290-303.
72. Weller R, Ormerod AD, Hobson RP, Benjamin NJ. A randomized trial of acidified nitrite cream in the treatment of tinea pedis. J Am Acad Dermatol 1998; 38:559-63.
73. Gomez EC, Huntley AC, Isseroff R, Tanji J. Efficacy of tolciclate solution in patients with tinea pedis. Clin Ther 1986;8:694-9.
74. Smith EB, Powell RF, Graham JL, Urlich JA. Topical undecylenic acid in tinea pedis: a new look. Int J Dermatol 1977;16:52.
75. Aly R, Bayles CI, Oakes RA, Bibel DJ, Maibach HI. Topical griseofulvin in the treatment of dermatophytoses. Clin Exp Dermatol 1994;19:43-6.
76. Savin RC. Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis. J Am Acad Dermatol 1990;23(4 pt 2):807-9.
77. Savin R. Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil). Clin Exp Dermatol 1989;14:116-9.
78. Tausch I, Decroix J, Gwiezdzinski Z, Urvanowski S, Baran E, Ziarkiewicz M, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol 1998;37:128-44.
79. Hay RJ, McGregor JM, Wuite J, Ryatt KS, Ziegler C, Clayton YM. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatol 1995;132: 604-8.
80. De Keyser P, De Backer M, Massart DL, Wesstelinck KJ. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol 1994;130(suppl 43):22-5.
81. Kim J-H, Yoon KB. Single-blind randomized study of terbinafine vs. itraconazole in tinea pedis (two weeks vs. four weeks). In: Shuster S, Jafary MH, editors. Terbinafine in the treatment of superficial fungal infection. Proceeding of the Asia-Pacific Symposium on Lamisil. International Congress and Symposium, No. 205. London: Royal Society of Medicine Services; 1993. p. 17-20.
82. Voravutinon V. Double-blind comparative study of the efficacy and tolerability of terbinafine with itraconazole in patients with tinea pedis. In: Shuster S, Jafary MH, editors. Terbinafine in the treatment of superficial fungal infections. Proceeding of the Asia-Pacific Symposium on Lamisil. International Congress and Symposium, No. 205. London: Royal Society of Medicine Services; 1993. p. 11-6.
83. Won Y-H, Kim S-J, Lee H-W, et al. Clinical comparative study of terbinafine and itraconazole in the treatment of tinea pedis. In: Shuster S, Jafary MH, editors. Terbinafine in the treatment of superficial fungal infections. Proceeding of the Asia-Pacific Symposium on Lamisil. International Congress and Symposium, No. 205. London: Royal Society of Medicine Services; 1993. p. 7-10.
84. Bametson RS, Marley J, Bullen M, Brookman S, Cowen P, Ellis D, et al. Comparison of one week of oral terbinafine (250 mg/day) with four weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. Br J Dermatol 1998;139:675-8.
85. Patel A, Brookman SD, Bullen MU, Marley J, Ellis DH, Williams T, et al. Topical treatment of interdigital tinea pedis: terbinafine compared with clotrimazole. Australas J Dermatol 1999;40:197-200.
86. Schopf R, Hettler O, Brautigam M, Weidinger G, Kaben U, Mayser P, et al. Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double-blind, multicentre, 8-week clinical trial. Mycoses 1999;42:415-20.
87. Elewski B, Bergstresser PR, Hanifin J, Lesher J, Savin R, Shupack J, et al. Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole. J Am Acad Dermatol 1995;32(2 pt 1): 290-2.
88. Bergstresser PR, Elewski B, Hanifin J, Lesher J, Savin R, Shupack J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4- week treatment regimens. J Am Acad Dermatol 1993;28:648-51.
89. Evans EGV, Dodman B, Williamson DM, Brown GJ, Bowen RG. Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 1993;307:645-7.
90. Evans EGV. A comparison of terbinafine (Lamisil) 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks, in the treatment of tinea pedis. Br J Dermatol 1994; 130(suppl 43):12-4.
91. Ledezma E, Marcano K, Jorquera A, De Sousa L, Padilla M, Pulgar M, et al. Efficacy of ajoene in the treatment of tinea pedis: a double-blind and comparative study with terbinafine. J Am Acad Dermatol 2000; 43(5 pt 1):829-32.
92. Smith EB, Breneman DL, Griffith RF, Hebert AA, Hickman JG, Maloney JM, et al. Double-blind comparison of naftifine cream and clotrimazole/ betamethasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992;26:125-7.
93. Naftifine Podiatric Study Group. Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis. J Am Podiatr Med Assoc 1990;80:314-8.
94. Smith EB, Wiss K, Hanifin JM, Jordon RE, Rapini RP, Lasser AE, et al. Comparison of once- and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis. J Am Acad Dermatol 1990;22(6 pt 1):1116-7.
95. Suschka S, Fladung B, Merk HF. Clinical comparison of the efficacy and tolerability of once daily Canesten with twice daily Nizoral (clotrimazole 1% cream vs. ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis. Mycoses 2002; 45:91-6.
96. Ongley RC. Efficacy of topical miconazole treatment of tinea pedis. Can Med Assoc J 1978;119:353-4.
97. Roberts DT, Adriaans B, Gentles JC. A comparative study of once daily bifonazole cream versus twice daily miconazole cream in the treatment of tinea pedis. Mykosen 1985;28:550-2.
98. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol 1996;35: 591-3.